.svg){kind=small}
Jul-2026
Sales
Trend
6-Month
Product Count
SKUs
Avg Price
YoY Sales Change
YoY Price Change
Where to Buy
Constellation Cannabis is stocked at 171 licensed dispensaries across Washington, Massachusetts, and 2 other states, 161 of them in Washington, with the deepest coverage in Seattle, Tacoma, Spokane, Lynnwood, and Bellevue. Search by ZIP code or city below to find the closest one, or filter by product type if you are after a specific format.
Market Insights Snapshot
In July 2026, Constellation Cannabis concentrated revenue into three pillars: Concentrates at 34.78% share (yoy +18.93%, mom -14.68), Edible at 28.64% share (yoy -5.21%, mom +13.69), and Beverage at 16.16% share (yoy +9.12%, mom +7.86). The tail contracted as Pre-Roll fell to 8.33% share (yoy -27.03%, mom -34.25) and Flower slipped to 3.13% share (yoy -30.49%, mom -30.30), while Vapor Pens held 6.65% share (yoy -37.55%, mom +1.30) and Capsules, though only 2.30% share, posted yoy +103.47% with mom -5.12. With overall average price down 0.22% year over year and the top category averaging $22.30, the mix now leans into higher-value Concentrates alongside expanding ingestibles; this pattern implies the brand is trading away from commoditized inhalables toward differentiated formats that soften unit-price pressure despite a 1.95% brand-level yoy sales dip.
The shifts point to a portfolio tilt that can sustain relevance in Washington: Concentrates holding rank 4 in category suggests defensible visibility even with a 14.68% month-over-month pullback, while Edible’s 13.69% monthly rise and Beverage’s 7.86% monthly rise build counter-cyclical balance against Pre-Roll’s 34.25% monthly drop. With Capsules doubling year over year by 103.47% yet still only 2.30% of sales, the expansion headroom sits in ingestibles rather than Flower, which declined 30.49% year over year; the implication is a positioning advantage in non-flower formats where price elasticity is more favorable, allowing the brand to consolidate share in higher-rankable niches while de-emphasizing volatile smokeable segments.
Competitive Landscape
Constellation Cannabis ranks #4 in Washington Concentrates in July 2026, improving 3 positions year over year from #7, and slipping 1 position since its peak at #3 in June 2026; this places it 1 spot behind Dabstract at #3, which rose 1 rank YoY with a 5.16% sales lift, and 3 spots behind Ooowee at #1, which held its top rank while contracting by 6.90% YoY—an opening that contrasts with Constellation Cannabis’s upward rank movement by 3 positions and suggests share can be taken from incumbents; with Delectable Dabs static at #2 and up 1.12% YoY while Oleum Extracts (Oleum Labs) sits at #5 and declined 7.99% YoY, the pattern of Constellation Cannabis advancing from #7 to #4 as higher-ranked peers post flat to negative growth implies a window to regain the #3 position and test #2 if July 2026 trajectory persists.
Notable Products
With no SKU moving more than +50% month over month or falling below -10% in July 2026, the most directional shift is Gravity - Pink Lemonade Gummies 10-Pack (100mg) climbing +12.7% to rank 5 while Moonshot - Grape Nano Emulsified Hash Rosin Beverage (100mg THC, 1.7oz) slipped -4.5% to rank 7, indicating edible momentum outpacing one beverage flavor. Moonshot - Blue Raspberry Nano Emulsified Hash Rosin Beverage (100mg THC, 1.7oz) held rank 1 at +8.4% MoM as Gravity - CBN/CBD/THC 1:1:1 Berry Blast Solventless Hash Rosin Gummies 10-Pack (100mg CBN, 100mg CBD, 100mg THC) advanced +23.7% at rank 4, and six of the top ten are Beverage SKUs while four are Edible SKUs. The top three ranks split 2:1 between Beverage and Edible with the leading beverage at $20,362 and the leading edible at +8.8% MoM at rank 3, which points to a balanced but shifting mix where functional edibles gain share against a still-dominant beverage anchor. Overall, the pattern implies Constellation Cannabis is tilting toward a dual-pillar strategy that keeps beverages on top while expanding multi-cannabinoid gummies for incremental growth.
Top Selling Cannabis Brands
Data for this report comes from real-time sales reporting by participating cannabis retailers via their point-of-sale systems, which are linked up with Headset’s business intelligence software. Headset’s data is very reliable, as it comes digitally direct from our partner retailers. However, the potential does exist for misreporting in the instance of duplicates, incorrectly classified products, inaccurate entry of products into point-of-sale systems, or even simple human error at the point of purchase. Thus, there is a slight margin of error to consider. Brands listed on this page are ranked in the top twenty within the market and product category by total retail sales volume.
